Zoetis (NYSE:ZTS) Issues Earnings Results

Zoetis (NYSE:ZTS) issued its quarterly earnings data on Thursday. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.04, Briefing.com reports. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the prior year, the business posted $0.79 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Zoetis updated its FY 2020
Pre-Market guidance to 3.90-4.00 EPS and its FY20 guidance to $3.90-4.00 EPS.

Shares of NYSE ZTS traded up $1.96 during midday trading on Thursday, hitting $144.94. The company’s stock had a trading volume of 3,384,463 shares, compared to its average volume of 2,025,562. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. The business’s 50 day moving average is $136.94 and its two-hundred day moving average is $127.01. Zoetis has a 12-month low of $88.65 and a 12-month high of $146.26. The firm has a market cap of $67.90 billion, a P/E ratio of 47.84, a price-to-earnings-growth ratio of 3.10 and a beta of 0.81.

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, April 17th will be issued a $0.20 dividend. The ex-dividend date is Thursday, April 16th. This represents a $0.80 annualized dividend and a dividend yield of 0.55%. Zoetis’s payout ratio is 25.56%.

A number of brokerages have issued reports on ZTS. Raymond James began coverage on Zoetis in a research report on Thursday, January 9th. They set a “market perform” rating on the stock. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $142.00 price objective on the stock in a research report on Thursday, December 26th. Cfra upgraded Zoetis from a “buy” rating to a “strong-buy” rating and upped their price objective for the company from $147.00 to $160.00 in a research report on Thursday. Finally, Bank of America restated a “hold” rating and set a $145.00 price objective on shares of Zoetis in a research report on Wednesday. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $133.73.

In other news, EVP Andrew Fenton sold 12,705 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $120.30, for a total value of $1,528,411.50. Following the sale, the executive vice president now directly owns 21,530 shares in the company, valued at $2,590,059. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $134.58, for a total value of $158,669.82. Following the completion of the sale, the executive vice president now owns 12,642 shares in the company, valued at $1,701,360.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 125,001 shares of company stock worth $15,342,770. Company insiders own 0.29% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: What causes a stock to be most active?

Earnings History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.